



## ASX Announcement

4 December 2025

## ECS Launches AVANI AVA: Targeted Medicinal Cannabis Products for Women's Health

### Highlights:

- ECS to launch AVANI AVA, a new medicinal cannabis brand tailored to women's health, in January 2026
- Initial range includes pessaries, capsules, topical cream and flower, designed to address the strong and growing demand for gender-specific treatment
- AVANI AVA strengthens ECS's differentiated B2C portfolio and supports further growth across pharmacy, prescriber and export channels

ECS Botanics Holdings Ltd (ASX: ECS) ("ECS" or the "Company"), a leading medicinal cannabis company, is pleased to announce the forthcoming launch of AVANI AVA, a new range of medicinal cannabis products designed to address the specific health needs of women.

Women now account for more than 40% of medicinal cannabis approvals under Australia's Special Access Scheme Category B (SAS-B), highlighting a growing demand for treatments tailored to female health conditions. ECS has developed AVANI AVA in direct response to this trend, leveraging its vertically integrated operations and formulation expertise to deliver carefully designed products across a range of delivery formats.

The initial AVANI AVA range will launch in January 2026, with products formulated to support management of conditions commonly reported by women under the SAS-B program.

### Initial Range Overview:

- **Pessaries:** 5mg THC / 25mg CBD formulated for targeted and rapid local delivery, reflecting areas of unmet need commonly reported by women under SAS-B approvals.
- **Flower:** 22% THC cultivar selected for its naturally sweet, fruity aroma and balanced terpene profile (including limonene and linalool influences), aligned with patient preference trends observed in women's-health prescribing.
- **Topical Cream:** 200mg THC / 200mg CBD topical cream incorporating a terpene-inspired aromatic blend for localised application.
- **Capsules:** Low-dose 5mg THC capsule designed for controlled dosing, informed by prescriber demand for low-impact oral formats in women's-health contexts.

AVANI AVA builds on the momentum of ECS's Avani-branded range and forms part of the Company's broader strategy to deliver differentiated, clinically relevant products.



The Company expects AVANI AVA to enhance its position in the B2C market, deepen engagement with prescribers and pharmacists specialising in women's health and drive growth across domestic and export channels through CY2026.

ECS Botanics Managing Director, Nan-Maree Schoerie, said:

*"We've developed AVANI AVA to meet a clear need in the market for well-considered, targeted products that address real clinical issues faced by women. This range reflects our commitment to building trusted brands supported by high-quality formulations, and we believe it has strong potential to open new conversations with prescribers and pharmacists focused on women's health."*

Authorised for release by Nan-Maree Schoerie, Managing Director

-ENDS-

**Investors and Media**

Tim Dohrmann, NWR Communications

P: +61 468 420 846

E: [tim@nwrcommunications.com.au](mailto:tim@nwrcommunications.com.au)

**About ECS Botanics Holdings Ltd**

ECS Botanics Holdings Ltd (ASX: ECS) is an Australian medicinal cannabis cultivator and manufacturer located in Northwest Victoria. ECS utilises progressive and innovative cultivation methodologies to produce quality medicine in a sustainable way, adopting regenerative and organic horticultural practices and renewable energy sources. Licenced by the Australian Therapeutic Goods Administration to manufacture GMP (equivalent to PIC/S, EU agencies are all PIC/S members) certified products, ECS has become a leading provider of high quality, affordable medicinal cannabis.